Marcos Silva / Shutterstock.com
6 August 2020Big PharmaSarah Morgan
KIPA hires former Decode Genetics director
IP boutique KIPA has strengthened its team with the addition of Iceland-based patent attorney Thorlakur Jonsson.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Big Pharma
16 July 2020 A US federal court has thrown out an appeal from Ono Pharmaceutical and a Nobel Prize-winning immunologist, in a dispute over who made groundbreaking discoveries in cancer therapy.
Americas
31 July 2020 The development of CRISPR technology is showing no signs of losing momentum, and Arbor Biotechnologies is one company that is taking full advantage of this. We spoke to Kelly Morgan, senior director, head of IP and legal at the company to find out more.
Editor's picks
Editor's picks
Big Pharma
16 July 2020 A US federal court has thrown out an appeal from Ono Pharmaceutical and a Nobel Prize-winning immunologist, in a dispute over who made groundbreaking discoveries in cancer therapy.
Americas
31 July 2020 The development of CRISPR technology is showing no signs of losing momentum, and Arbor Biotechnologies is one company that is taking full advantage of this. We spoke to Kelly Morgan, senior director, head of IP and legal at the company to find out more.
Big Pharma
16 July 2020 A US federal court has thrown out an appeal from Ono Pharmaceutical and a Nobel Prize-winning immunologist, in a dispute over who made groundbreaking discoveries in cancer therapy.
Americas
31 July 2020 The development of CRISPR technology is showing no signs of losing momentum, and Arbor Biotechnologies is one company that is taking full advantage of this. We spoke to Kelly Morgan, senior director, head of IP and legal at the company to find out more.